Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial

Beni-Suef University Journal of Basic and Applied Sciences

Table 1 Baseline and demographic data in both groups

Parameters	Sitagliptin (n = 82)	Empagliflozin (n = 75)	p-Value
Gender, n%
Male	33 (40.2%)	40 (53.3%)	< 0.001
Female	49 (59.8%)	35 (46.7%)	< 0.001
Age (years)
Min.–Max	30–67	21–70	0.948
Mean ± SD	53.524 ± 8.6670	53.427 ± 10.2300	0.948
Body weight (kg)
Min.–Max	54–123	59–145	0.411
Mean ± SD	91.055 ± 15.4488	93.267 ± 17.9548	0.411
HbA1c (%)
Min.–Max	7.0–10.0	7.0–10.0	0.227
Mean ± SD	8.495 ± 1.0000	8.316 ± 0.8350	0.227
FPG (mg/dl)
Min.–Max	84–401	88–289	0.030
Mean ± SD	184.244 ± 64.4208	164.600 ± 45.1580	0.030
PP (mg/dl)
Min.–Max	127–481	91–869	0.409
Mean ± SD	271.915 ± 89.2699	258.573 ± 110.2033	0.409
LDL (mg/dl)
Min.–Max	66–187	42–223	0.258
Mean ± SD	124.902 ± 28.5024	130.120 ± 28.9491	0.258
Total Cholesterol (mg/dl)
Min.–Max	140–306	112–307	0.532
Mean ± SD	203.098 ± 39.1879	207.000 ± 38.7748	0.532
HDL (mg/dl)
Min.–Max	30–66	30–67	0.197
Mean ± SD	46.110 ± 10.5993	43.960 ± 10.1893	0.197
TG (mg/dl)
Min.–Max	90–387	92–463	0.270
Mean ± SD	207.134 ± 72.7629	194.800 ± 66.7472	0.270
SBP (mmHg)
Min.–Max	110–190	110–240	0.418
Mean ± SD	134.512 ± 16.2847	136.733 ± 17.8298	0.418
DBP (mmHg)
Min.–Max	70–140	60–110	0.193
Mean ± SD	83.049 ± 13.5345	85.600 ± 10.8416	0.193